image
Healthcare - Biotechnology - NASDAQ - US
$ 28.32
-5.51 %
$ 1.64 B
Market Cap
2.43
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one AGIO stock under the worst case scenario is HIDDEN Compared to the current market price of 28.3 USD, Agios Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one AGIO stock under the base case scenario is HIDDEN Compared to the current market price of 28.3 USD, Agios Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one AGIO stock under the best case scenario is HIDDEN Compared to the current market price of 28.3 USD, Agios Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart AGIO

image
$65.0$65.0$60.0$60.0$55.0$55.0$50.0$50.0$45.0$45.0$40.0$40.0$35.0$35.0$30.0$30.0$25.0$25.0$20.0$20.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
36.5 M REVENUE
36.07%
-426 M OPERATING INCOME
-8.75%
674 M NET INCOME
291.35%
-390 M OPERATING CASH FLOW
-31.68%
363 M INVESTING CASH FLOW
51.70%
14.4 M FINANCING CASH FLOW
165.82%
8.73 M REVENUE
-18.68%
-107 M OPERATING INCOME
14.72%
-89.3 M NET INCOME
7.49%
-111 M OPERATING CASH FLOW
16.28%
113 M INVESTING CASH FLOW
329.03%
1.62 M FINANCING CASH FLOW
-66.56%
Balance Sheet Agios Pharmaceuticals, Inc.
image
Current Assets 966 M
Cash & Short-Term Investments 894 M
Receivables 4.11 M
Other Current Assets 67.8 M
Non-Current Assets 698 M
Long-Term Investments 638 M
PP&E 54.6 M
Other Non-Current Assets 4.72 M
53.73 %4.08 %38.38 %3.28 %Total Assets$1.7b
Current Liabilities 81.2 M
Accounts Payable 16.6 M
Short-Term Debt 16.8 M
Other Current Liabilities 47.7 M
Non-Current Liabilities 41.1 M
Long-Term Debt 0
Other Non-Current Liabilities 41.1 M
13.61 %13.73 %39.05 %33.61 %Total Liabilities$122.2m
EFFICIENCY
Earnings Waterfall Agios Pharmaceuticals, Inc.
image
Revenue 36.5 M
Cost Of Revenue 4.16 M
Gross Profit 32.3 M
Operating Expenses 458 M
Operating Income -426 M
Other Expenses -1.1 B
Net Income 674 M
800m800m600m600m400m400m200m200m00(200m)(200m)(400m)(400m)(600m)(600m)36m(4m)32m(458m)(426m)1b674mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
88.59% GROSS MARGIN
88.59%
-1166.47% OPERATING MARGIN
-1166.47%
1845.92% NET MARGIN
1845.92%
43.72% ROE
43.72%
40.51% ROA
40.51%
-24.99% ROIC
-24.99%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Agios Pharmaceuticals, Inc.
image
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)(350m)(350m)(400m)(400m)(450m)(450m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 674 M
Depreciation & Amortization 5.65 M
Capital Expenditures -1.68 M
Stock-Based Compensation 42.8 M
Change in Working Capital -19.8 M
Others -1.11 B
Free Cash Flow -392 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Agios Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for AGIO of $55.3 , with forecasts ranging from a low of $45 to a high of $71 .
AGIO Lowest Price Target Wall Street Target
45 USD 58.90%
AGIO Average Price Target Wall Street Target
55.3 USD 95.22%
AGIO Highest Price Target Wall Street Target
71 USD 150.71%
Price
Max Price Target
Min Price Target
Average Price Target
757570706565606055555050454540403535303025252020Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 22
6. Ownership
Insider Ownership Agios Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
1.14 M USD 7
3-6 MONTHS
178 K USD 3
6-9 MONTHS
2.42 M USD 4
9-12 MONTHS
1.29 M USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates AGIO's earnings beat estimates in the first quarter of 2025, while revenues miss the same. zacks.com - 2 weeks ago
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025 CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025, at 8:00 am PT/11:00 am ET. globenewswire.com - 2 weeks ago
Agios Pharmaceuticals, Inc. (AGIO) Q1 2025 Earnings Call Transcript Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Chris Taylor – Vice President-Investor Relations and Corporate Communications Brian Goff – Chief Executive Officer Sarah Gheuens – Chief Medical Officer, Head-Research and Development Tsveta Milanova – Chief Commercial Officer Cecilia Jones – Chief Financial Officer Conference Call Participants Gregory Renza – RBC Capital Markets Alec Stranahan – Bank of America Divya Rao – TD Cowen Hiro Nagayumi – Cantor Emily Bodnar – H.C. Wainwright Tessa Romero – JPMorgan Operator Good morning, and welcome to Agios' First Quarter 2025 Conference Call. seekingalpha.com - 2 weeks ago
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.55 per share versus the Zacks Consensus Estimate of a loss of $1.80. This compares to loss of $1.45 per share a year ago. zacks.com - 2 weeks ago
Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights – U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND ® (mitapivat) in Thalassemia,  with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track, with Topline Results Expected in Late 2025; Potential U.S. Commercial Launch in 2026 – – Tebapivat Advancing in Clinical Trials for Lower-Risk Myelodysplastic Syndromes (LR-MDS) and Sickle Cell Disease – – PYRUKYND Net Revenue of $8.7 Million in Q1; Cash, Cash Equivalents and Marketable Securities of $1.4 Billion as of March 31, 2025 – CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today reported business highlights and financial results for the first quarter ended March 31, 2025. globenewswire.com - 2 weeks ago
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 3 weeks ago
Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025 CAMBRIDGE, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, May 1, 2025, at 8:00 a.m. globenewswire.com - 1 month ago
New Strong Sell Stocks for April 8th AFLYY, AGIO and ARLP have been added to the Zacks Rank #5 (Strong Sell) List on April 8, 2025. zacks.com - 1 month ago
New Strong Sell Stocks for April 3rd AGIO, CHGG and EFX have been added to the Zacks Rank #5 (Strong Sell) List on April 3, 2025. zacks.com - 1 month ago
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the grant of inducement equity awards outside of the Company's 2023 Stock Incentive Plan to its newly appointed Chief Corporate Development & Strategy Officer, Krishnan Viswanadhan. The grants were approved by the Board of Directors effective as of March 5, 2025, as inducements material to Mr. Viswanadhan entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). globenewswire.com - 2 months ago
Agios to Present at Upcoming Investor Conferences CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the following conferences: Leerink Global Healthcare Conference 2025: Fireside chat on Tuesday, March 11, 2025, at 10:50 a.m. globenewswire.com - 2 months ago
Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025 CAMBRIDGE, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the TD Cowen 45th Annual Healthcare Conference on Monday, March 3, 2025, at 10:30 a.m. ET. globenewswire.com - 2 months ago
8. Profile Summary

Agios Pharmaceuticals, Inc. AGIO

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 1.64 B
Dividend Yield 0.00%
Description Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Contact 88 Sidney Street, Cambridge, MA, 02139-4169 https://www.agios.com
IPO Date July 24, 2013
Employees 486
Officers Mr. Brian M. Goff M.B.A. Chief Executive Officer & Director Dr. Craig B. Thompson M.D. Co-Founder Ms. Tsveta Milanova Chief Commercial Officer Dr. Lewis Clayton Cantley Ph.D. Co-Founder Dr. Sarah Gheuens M.D., Ph.D. Chief Medical Officer and Head of Research & Development Dr. Shin-San Su Ph.D. Co-Founder Mr. T. J. Washburn Vice President, Controller & Principal Accounting Officer Ms. Cecilia Jones Chief Financial Officer Mr. James William Burns Corporate Secretary & Chief Legal Officer Dr. Tak Wah Mak D.Sc., FRSC, Ph.D. Co-Founder